{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:43Z","timestamp":1788778843422,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Objective<\/jats:title>\n                    <jats:p>This study explored the status of patients with chronic myeloid leukemia following the safe discontinuation of frontline or second\u2010line bosutinib treatment. The goal was to assess the long\u2010term outcomes and factors influencing treatment\u2010free remission (TFR) following cessation of bosutinib therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The median duration of bosutinib treatment among 16 patients was 48\u2009months. All patients achieved a deep molecular response before bosutinib discontinuation, which was sustained for a median pre\u2010cessation period of 27\u2009months. Patients were monitored for molecular response and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After bosutinib discontinuation, the major molecular response was lost in six patients: within 6\u2009months in five patients and at 19\u2009months in one patient. All six patients achieved a major molecular response after at least 3\u2009months of bosutinib re\u2010treatment. Ten patients exhibited successful TFR without loss of major molecular response for a median duration of 48 (16\u2013101) months. Kaplan\u2013Meier analysis revealed a 68.8% treatment\u2010free survival at 12\u2009months. After bosutinib cessation, eight patients developed Grade 1\u20132 withdrawal syndrome. No differences were observed in the clinical characteristics or bosutinib treatment between patients with TFR at 12\u2009months (TFR group) and those without remission (recurrence group), except for the deep molecular response duration before bosutinib cessation (31 vs. 24\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). T\u2010cell profiling using flow cytometry revealed a higher percentage of effector memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells at 1 and 3\u2009months after bosutinib discontinuation in the TFR group than in the recurrence group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bosutinib can be safely discontinued under certain conditions, similar to other tyrosine kinase inhibitors. Additionally, T\u2010cell profile analysis before and after bosutinib discontinuation may predict successful TFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.70822","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:48:41Z","timestamp":1745891321000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bosutinib for Successful Treatment\u2010Free Remission in Chronic Myeloid Leukemia"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-7462","authenticated-orcid":false,"given":"Yuki","family":"Fujioka","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology Akita University Graduate School of Medicine  Akita Japan"},{"name":"Division of Central Laboratory Akita University Hospital  Akita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Abumiya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Akita University Hospital  Akita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell Therapy Hamamatsu University Hospital  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology Akita University Graduate School of Medicine  Akita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1895.1895"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2295-0"},{"key":"e_1_2_11_10_1","unstructured":"NCCN \u201cChronic Myeloid Leukemia \u201dNCCN Clinical Practice Guidelines in Oncology 2024 Version 3.2025."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03865-2"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745992"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165001"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16718"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03117-7"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235904"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1722-8"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2239-8"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02878-x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03435-4"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0101-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13801"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03144-4"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1146-z"},{"issue":"1","key":"e_1_2_11_29_1","first-page":"3580","article-title":"Nilotinib and Dasatinib Evoked Distinct Immune Effects During Tfr Phase of Each Discontinuation Trial","volume":"138","author":"Fujioka Y.","year":"2021","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191009"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3158"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23724"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8941260"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201540"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02074-w"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.004"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14518"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.70822","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T07:16:24Z","timestamp":1771139784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/cam4.70822"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70822","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"2024-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70822"}}